JHEP Reports

Article	Citations
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper	311
Limitations of non-invasive tests for assessment of liver fibrosis	121
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic	105
Non-alcoholic fatty liver disease: A patient guideline	104
NAFLD and liver transplantation: Disease burden, current management and future challenges	88
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial	81
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma	78
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors	78
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment	77
New targets for NAFLD	72
Organoids to model liver disease	69
Lipid alterations in chronic liver disease and liver cancer	64
Where does TIPS fit in the management of patients with cirrhosis?	61
Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction	60
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma	55
Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity	55
NAFLD and MAFLD as emerging causes of HCC: A populational study	50
Novel vectors and approaches for gene therapy in liver diseases	50
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy	50
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B	50
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease	49
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area	49
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study	49
The liver matrisome – looking beyond collagens	48
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg	45

Gut dysbiosis as a driver in alcohol-induced liver injury	44
Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials	43
New frontiers in liver resection for hepatocellular carcinoma	41
Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy	36
Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease	35
Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD	34
Combined alcoholic and non-alcoholic steatohepatitis	34
Assessing the impact of COVID-19 on liver cancer management (CERO-19)	34
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases	33
Nuclear deformation mediates liver cell mechanosensing in cirrhosis	33
Extended hypothermic oxygenated machine perfusion enables ex situ preservation of porcine livers for up to 24 hours	33
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis	32
Understanding the cellular interactome of non-alcoholic fatty liver disease	32
miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction	31
Real-world experience with obeticholic acid in patients with primary biliary cholangitis	31
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation	30
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease	30
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis	30
De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA	30
Cell of origin in biliary tract cancers and clinical implications	29
Evaluation of liver tumour response by imaging	29
Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD	28
Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the past	28
Evaluating causality of cellular senescence in non-alcoholic fatty liver disease	28
Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension	28
The ALBI score: From liver function in patients with HCC to a general measure of liver function	28
A human liver chimeric mouse model for non-alcoholic fatty liver disease	27
New insights on the role of vascular endothelial growth factor in biliary pathophysiology	27
Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation	26
Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS	26
Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis	26
Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease	25
Approach to the patient with acute severe autoimmune hepatitis	25
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort	25
Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction	25
The role of cGAS-STING signalling in liver diseases	25
Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis	25
Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis	24
Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review	24
European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?	24
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2	24
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice	24
NASH-related increases in plasma bile acid levels depend on insulin resistance	24
Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions	23
Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D	22
New insights into the pathophysiology and clinical care of rare primary liver cancers	22
Adding the oxygen carrier M101 to a cold-storage solution could be an alternative to HOPE for liver graft preservation	22
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation	22
Influence of surgical approach and quality of resection on the probability of cure for early-stage HCC occurring in cirrhosis	22
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma	22

Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets	22
Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort	22
The neurogliovascular unit in hepatic encephalopathy	22
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study	21
Embedding assessment of liver fibrosis into routine diabetic review in primary care	21
The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes	21
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey	21
A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients	21
Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities	21
ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis	20
Stratification of patients in NASH clinical trials: A pitfall for trial success	20
Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma	20
Using cell-free DNA for HCC surveillance and prognosis	20
Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA	20
Early transplantation maximizes survival in severe acute-on-chronic liver failure: Results of a Markov decision process model	20
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance	20
Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents	19
Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis	19
Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis	19
Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities	19
Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC	18
Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease	18
TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload	18
Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease	18
Elevated plasma ICAM1 levels predict 28-day mortality in cirrhotic patients with COVID-19 or bacterial sepsis	18
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication	18
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care	17
Case-finding strategies in non-alcoholic fatty liver disease	17
Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy	17
Features and outcome of AIH patients without elevation of IgG	17
Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer	17
Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines	16
Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections	16
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity	16
Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B	16
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection	16
Are the new genetic tools for diagnosis of Wilson disease helpful in clinical practice?	16
Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis	16
Novel role of macrophage TXNIP-mediated CYLD–NRF2–OASL1 axis in stress-induced liver inflammation and cell death	16
Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine	16
High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma	16
Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis	16
Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma	15
Non-invasive biomarkers of Fontan-associated liver disease	15
Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2 mouse	15
Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor	15
Treating hepatitis D with bulevirtide – Real-world experience from 114 patients	15
Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event	15
TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection	15
From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?	15
XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression	15
Hepatic microbiome in healthy lean and obese humans	14
Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county	14
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination	14
Epigenetics of alcohol-related liver diseases	14
Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank	14
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure	14
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials	14
Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates	14
Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis	14
Management of splanchnic vein thrombosis	14
Abnormal liver tests in patients with SARS-CoV-2 or influenza – prognostic similarities and temporal disparities	14
Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure	14
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis	13
Hepatopulmonary syndrome	13
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis	13
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis	13
ZBTB20 regulates WNT/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis	13
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis	13
Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators	13
Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis	12
Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis	12
Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy	12
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice	12
Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade	12
Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination	12
Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis	12
CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson’s disease	11
A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation	11
Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure	11

Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis	11
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction	11
Cellular origins of regenerating liver and hepatocellular carcinoma	11
Ablation of liver Fxr results in an increased colonic mucus barrier in mice	11
Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness	11
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma	11
Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis	11
Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease	10
Hepatic sarcoidosis: Clinical characteristics and outcome	10
Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system	10
Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C	10
Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV	10
Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome	10
International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria	10
Abnormal brain oxygen homeostasis in an animal model of liver disease	10
Higher subcutaneous adipose tissue radiodensity is associated with increased mortality in patients with cirrhosis	10
IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer	10
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD	10
Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis	9
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	9
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals	9
Evidence for long-term association of virion-delivered HBV core protein with cccDNA independently of viral protein production	9
Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score	9
Defatting strategies in the current era of liver steatosis	9
Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults	9
Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection	9
Spleen volume-based non-invasive tool for predicting hepatic decompensation in people with compensated cirrhosis (CHESS1701)	9
Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis	9
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis	9
Emerging roles of circular RNAs in liver cancer	9
Hyperammonaemia induces mitochondrial dysfunction and neuronal cell death	9
(13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle	9
Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p	9
Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction	9
Hepatic decompensation is accelerated in patients with cirrhosis and alpha-1 antitrypsin Pi∗MZ genotype	9
Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B	8
Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma	8
Hepatocyte mARC1 promotes fatty liver disease	8
Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study	8
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort	8
Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada	8
Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study	8
Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells	8
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma	8
Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF	8
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	8
Saturated fatty acid-enriched small extracellular vesicles mediate a crosstalk inducing liver inflammation and hepatocyte insulin resistance	8
Acetaminophen-induced reduction of NIMA-related kinase 7 expression exacerbates acute liver injury	8
Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B	8
Sex disparities in waitlisting and liver transplant for acute liver failure	8
A small animal model of chronic hepatitis E infection using immunocompromised rats	8
Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis	7
Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States	7
Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters	7
Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis	7
Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS	7
Blue-collar work is a risk factor for developing IgG4-related disease of the biliary tract and pancreas	7
Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag	7
SCYL3, as a novel binding partner and regulator of ROCK2, promotes hepatocellular carcinoma progression	7
Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD	7
Use of albumin infusion for cirrhosis-related complications: An international position statement	7
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial	7
A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice	7
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	7
Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice	7
Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study	7
Quality and reproducibility during the COVID-19 pandemic	7
Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts	7
Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice	7
Systemic iron reduction by venesection alters the gut microbiome in patients with haemochromatosis	6
Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus	6
C–C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease	6
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis	6
Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection	6
High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia	6
Differential and organ-specific functions of organic solute transporter α and β in experimental cholestasis	6
Conversion of hepatitis B virus relaxed circular to covalently closed circular DNA is supported in murine cells	6
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation	6
The importance of adequate oxygenation during hypothermic machine perfusion	6
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	6
Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease	6
Zinc finger transcription factor Egf1 promotes non-alcoholic fatty liver disease	6
Differential blood transcriptome modules predict response to corticosteroid therapy in alcoholic hepatitis	6
Cathelicidin promotes liver repair after acetaminophen-induced liver injury in mice	6
Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer	6
Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas	6
Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis	6
Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis	5
Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection	5
Cirrhosis management in a major referral center during COVID-19	5
Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging	5
Environmental exposures are important risk factors for advanced liver fibrosis in African American adults	5
A new mouse model of radiation-induced liver disease reveals mitochondrial dysfunction as an underlying fibrotic stimulus	5
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV	5
Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure	5